代谢综合征与帕金森病统一评分量表评分变化的相关性
该研究是对NINDS帕金森病长期研究1中1,022例参与者的二次分析,比较符合代谢综合征修正标准者与不符合者从随机化到3年的UPDRS和SDMT评分变化。结果显示,代谢综合征患者总UPDRS和运动UPDRS年增幅更大,而SDMT变化无差异。
要点
- 代谢综合征与帕金森病患者总UPDRS和运动UPDRS评分随时间增加更快相关。
- 代谢综合征与SDMT评分变化无显著差异。
- 该发现需进一步研究确认。
核心结论
- 符合代谢综合征修正标准的帕金森病患者总UPDRS评分随时间增加更多,主要归因于运动评分的增加。
研究设计与样本
- 本研究为对NINDS帕金森病长期研究1(一项肌酸随机安慰剂对照试验)中1,022例参与者的二次分析。
- 参与者根据国家胆固醇教育计划成人治疗组III修正标准分为有或无代谢综合征,仅纳入连续年度访视中代谢综合征状态相同者。
- 比较从随机化到3年UPDRS和SDMT评分的变化。
主要发现
- 代谢综合征组(n=396)相比无代谢综合征组(n=626)年龄更大(平均[SD] 63.9[8.1] vs 59.9[9.4]岁;p<0.0001)。
- 代谢综合征组男性比例更高(75.3% vs 57.0%;p<0.0001)。
- 代谢综合征组尿酸水平更高(男性5.7[1.3] vs 5.3[1.1] mg/dL,女性4.9[1.3] vs 3.9[0.9] mg/dL,p<0.0001)。
- 代谢综合征患者总UPDRS年增加额外0.6(0.2)单位(p=0.02),运动UPDRS年增加额外0.5(0.2)单位(p=0.01)。
- SDMT评分变化无差异。
关键数值与推荐
- 代谢综合征采用国家胆固醇教育计划成人治疗组III修正标准定义。
- 总UPDRS年增加额外0.6(0.2)单位(p=0.02),运动UPDRS年增加额外0.5(0.2)单位(p=0.01)。
临床怎么用
- 在帕金森病患者中,评估代谢综合征可能有助于识别运动症状进展更快的个体。
局限性
- 本研究为二次分析,结果需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the association between metabolic syndrome and the Unified Parkinson's Disease Rating Scale (UPDRS) scores and, secondarily, the Symbol Digit Modalities Test (SDMT). METHODS: This is a secondary analysis of data from 1,022 of 1,741 participants of the National Institute of Neurological Disorders and Stroke Exploratory Clinical Trials in Parkinson Disease Long-Term Study 1, a randomized, placebo-controlled trial of creatine. Participants were categorized as having or not having metabolic syndrome on the basis of modified criteria from the National Cholesterol Education Program Adult Treatment Panel III. Those who had the same metabolic syndrome status at consecutive annual visits were included. The change in UPDRS and SDMT scores from randomization to 3 years was compared in participants with and without metabolic syndrome. RESULTS: Participants with metabolic syndrome (n = 396) compared to those without (n = 626) were older (mean [SD] 63.9 [8.1] vs 59.9 [9.4] years; p < 0.0001), were more likely to be male (75.3% vs 57.0%; p < 0.0001), and had a higher mean uric acid level (men 5.7 [1.3] vs 5.3 [1.1] mg/dL, women 4.9 [1.3] vs 3.9 [0.9] mg/dL, p < 0.0001). Participants with metabolic syndrome experienced an additional 0.6- (0.2) unit annual increase in total UPDRS (p = 0.02) and 0.5- (0.2) unit increase in motor UPDRS (p = 0.01) scores compared with participants without metabolic syndrome. There was no difference in the change in SDMT scores. CONCLUSIONS: Persons with Parkinson disease meeting modified criteria for metabolic syndrome experienced a greater increase in total UPDRS scores over time, mainly as a result of increases in motor scores, compared to those who did not. Further studies are needed to confirm this finding. CLINICALTRIALSGOV IDENTIFIER: NCT00449865.
引用
- Leehey M, Luo S, Sharma S, et al. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017. PMID: 28972194. doi:10.1212/WNL.0000000000004572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。